Orexigen Therapeutics (OREX) Sets New 12-Month Low at $0.84

Orexigen Therapeutics, Inc. (NASDAQ:OREX)’s share price reached a new 52-week low during trading on Wednesday . The company traded as low as $0.84 and last traded at $0.92, with a volume of 227000 shares trading hands. The stock had previously closed at $0.92.

A number of equities analysts have recently commented on the stock. ValuEngine upgraded shares of Orexigen Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Friday, February 2nd. Zacks Investment Research upgraded shares of Orexigen Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, January 16th.

The company has a market cap of $17.81, a PE ratio of -0.09 and a beta of 2.07. The company has a current ratio of 2.00, a quick ratio of 1.71 and a debt-to-equity ratio of -2.75.

Orexigen Therapeutics (NASDAQ:OREX) last announced its earnings results on Monday, November 13th. The biopharmaceutical company reported ($1.35) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.13) by $0.78. Orexigen Therapeutics had a negative net margin of 192.65% and a negative return on equity of 824.15%. The business had revenue of $18.90 million during the quarter, compared to analyst estimates of $24.20 million. During the same period in the previous year, the business posted $1.12 earnings per share. Orexigen Therapeutics’s revenue for the quarter was up 170.0% on a year-over-year basis. research analysts anticipate that Orexigen Therapeutics, Inc. will post -10.08 earnings per share for the current fiscal year.

A hedge fund recently raised its stake in Orexigen Therapeutics stock. Wells Fargo & Company MN raised its stake in shares of Orexigen Therapeutics, Inc. (NASDAQ:OREX) by 2.5% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 45,638 shares of the biopharmaceutical company’s stock after purchasing an additional 1,100 shares during the quarter. Wells Fargo & Company MN owned 0.30% of Orexigen Therapeutics worth $132,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 34.86% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: This article was published by Markets Daily and is owned by of Markets Daily. If you are reading this article on another website, it was stolen and reposted in violation of international trademark and copyright laws. The correct version of this article can be accessed at https://www.themarketsdaily.com/2018/02/14/orexigen-therapeutics-orex-sets-new-12-month-low-at-0-84.html.

About Orexigen Therapeutics

Orexigen Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the treatment of obesity. The Company’s product, Contrave, is approved in the United States by the United States Food and Drug Administration as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kilograms per square meter or greater (obese) or 27 kilograms per square meter or greater (overweight) in the presence of a weight-related comorbid condition.

Receive News & Ratings for Orexigen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orexigen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply